弥漫性大B细胞淋巴瘤中B细胞受体与PI3K信号通路的靶向治疗
本文综述弥漫性大B细胞淋巴瘤(DLBCL)中B细胞受体(BCR)信号及其下游NF-κB与磷脂酰肌醇3-激酶(PI3K)级联的分子病理作用。约三分之一DLBCL患者对当前标准化疗免疫治疗不愈,部分亚型存在BCR通路组分基因改变,故BCR及PI3K通路被视为潜在治疗靶点,本文总结相关认识及治疗转化思路。
要点
- BCR信号对正常及恶性B细胞的发育、生长和存活至关重要
- 约三分之一DLBCL患者对当前标准化疗免疫治疗不愈
- 部分DLBCL亚型存在BCR通路核心组分或下游效应分子的基因改变
核心结论
- BCR信号及其下游NF-κB与PI3K级联被提出作为DLBCL患者的潜在治疗靶点
- PI3K介导的信号作为BCR激活的主要效应之一,在DLBCL的发病与存活中起关键作用
研究设计与样本
- 本文为综述,总结当前对DLBCL中BCR信号特别是PI3K通路的认识及其治疗应用
主要发现
- DLBCL是异质性诊断类别,包含由不同遗传学异常决定的分子亚型并影响患者结局
- 约三分之一DLBCL患者不能被当前标准化疗免疫治疗治愈
- 多种分析揭示部分DLBCL亚型中存在BCR核心组分或其下游信号效应分子的基因改变
临床怎么用
- 基于BCR及下游PI3K通路在DLBCL发病与存活中的作用,可探索将其作为治疗靶点
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous diagnostic category comprising distinct molecular subtypes characterized by diverse genetic aberrations that dictate patient outcome. As roughly one-third of patients with DLBCL are not cured by current standard chemoimmunotherapy, a better understanding of the molecular pathogenesis is warranted to improve outcome. B-cell receptor (BCR) signaling is crucial for the development, growth, and survival of normal B cells and a substantial fraction of malignant B cells. Various analyses revealed genetic alterations of central components of the BCR or its downstream signaling effectors in some subtypes of DLBCL. Thus, BCR signaling and the downstream NF-κB and phosphatidylinositol 3-kinase (PI3K) cascades have been proposed as potential targets for the treatment of patients with DLBCL. As one of the main effectors of BCR activation, PI3K-mediated signals play a crucial role in the pathogenesis and survival of DLBCL. In this review, we summarize our current understanding of BCR signaling with a special focus on the PI3K pathway in DLBCL and how to use this knowledge therapeutically.
引用
- Xu W, Berning P, Lenz G, et al. Targeting B-cell receptor and PI3K signaling in diffuse large B-cell lymphoma. Blood. 2021. PMID: 34320160. doi:10.1182/blood.2020006784
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。